2
Clinical Trials associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)A Phase I Clinical Trial Assessing the Safety and Feasibility of Administration of pNGVL4a-CRT/E7(Detox) DNA Vaccine Using the Intramuscular TriGridTM Delivery System in Combination With Cyclophosphamide in HPV-16 Associated Head and Neck Cancer Patients
This study will test the safety of an HPV DNA vaccine after it is injected into your muscle using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help your body's immune system to recognize HPV-infected and associated cancer cells. In addition to giving the vaccine using an electroporation device, we are giving the vaccine in combination with an immunomodulatory agent to further enhance immune responses against HPV-infected and associated cancer cells.
A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
This study will test the efficacy and safety of different routes of administration of a DNA vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment groups. Subjects enrolled in the first two groups will receive vaccination intradermally with a needle-free delivery device. Subjects enrolled in groups 3 and 4 will receive vaccination intramuscularly. Subjects enrolled in groups 5 and 6 will receive vaccine intralesionally.
100 Clinical Results associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)
100 Translational Medicine associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)
100 Patents (Medical) associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)
100 Deals associated with pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.)